Testing duvakitug for active Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old (or 16 to 18 if fully developed).
- You have had moderately to severely active Crohn's disease for at least 3 months.
- You have tried other treatments (like conventional therapies or advanced therapies) and they didn't work well enough, stopped working, or caused side effects.
- You are not currently taking certain medications without stable doses, and you have not been treated with another drug like duvakitug before.
- You do not have ulcerative colitis, indeterminate colitis, or missing large sections of your bowel.
- You do not have high-grade dysplasia (abnormal cells) in your digestive tract.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.